Clinical Trial Update: A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update describes a study to assess adverse events, changes in disease activity, and pharmacokinetics of oral emraclidine in adult pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Emraclidine (Emraclidine)

Snippet

Sponsor: AbbVie | Conditions: Schizophrenia | Phase 2 | Status: RECRUITING